Guided Therapeutics (GTHP) Capital Expenditures (2011 - 2022)

Guided Therapeutics has disclosed Capital Expenditures across 8 years of filings, most recently posting $3000.0 for Q4 2022.

• Capital Expenditures for Q4 2022 came in at $3000.0, down 25.0% year-over-year; the trailing twelve-month figure through Sep 2023 was $3000.0 (down 90.62% YoY), and the FY2025 annual result was $2000.0, changed N/A from the prior year.
• Capital Expenditures came in at $3000.0 for Q4 2022 at Guided Therapeutics, up from -$3000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $17000.0 in Q2 2022 to a low of -$3000.0 in Q3 2022.
• The 3-year median for Capital Expenditures is $4000.0 (2021), against an average of $5111.1.
• Peak annual rise in Capital Expenditures reached 1300.0% in 2022, while the deepest fall reached 160.0% in 2022.
• Guided Therapeutics' Capital Expenditures stood at $1000.0 in 2020, then surged by 300.0% to $4000.0 in 2021, then declined by 25.0% to $3000.0 in 2022.
• The last three Capital Expenditures figures came in at $3000.0 (Q4 2022), -$3000.0 (Q3 2022), and $17000.0 (Q2 2022), per Business Quant data.